Akineton

Extrapyramidal Disorders, Organophosphorus Compounds, Parkinson's Disease + 2 more
Treatment
20 Active Studies for Akineton

What is Akineton

BiperidenThe Generic name of this drug
Treatment SummaryBenztropine is a medication that blocks nerve signals in the brain and body. It is used to treat Parkinson's disease, symptoms caused by certain medications, and other nerve-related medical conditions.
Akinetonis the brand name
image of different drug pills on a surface
Akineton Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Akineton
Biperiden
1996
2

Effectiveness

How Akineton Affects PatientsBiperiden is a drug that helps to control certain physical symptoms, including sweating, muscle stiffness, and difficulty moving. It is commonly used to treat the side effects of certain drugs used to treat psychiatric disorders. When administered through injection, biperiden is effective in reducing or eliminating symptoms such as akathisia, akinesia, tremors, and oculogyric crisis.
How Akineton works in the bodyBiperiden is used to treat Parkinsonism, which occurs when the brain has too much activity from one type of nerve cells and not enough from another. Biperiden works by blocking the activity of the overactive nerve cells, restoring balance and improving symptoms.

When to interrupt dosage

The endorsed dosage of Akineton is contingent upon the recognized condition, including extrapyramidal reaction, Poisoning caused by Nicotine and Parkinson's Disease. The degree of dosage deviates, in line with the administration technique listed in the table underneath.
Condition
Dosage
Administration
Parkinson's Disease
2.0 mg,
, Oral, Tablet, Tablet - Oral
Organophosphorus Compounds
2.0 mg,
, Oral, Tablet, Tablet - Oral
Basal Ganglia Diseases
2.0 mg,
, Oral, Tablet, Tablet - Oral
Extrapyramidal Disorders
2.0 mg,
, Oral, Tablet, Tablet - Oral
Poisoning caused by Nicotine
2.0 mg,
, Oral, Tablet, Tablet - Oral

Warnings

Akineton has five contraindications and should not be used in combination with the conditions enumerated in the table below.Akineton Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Biperiden may interact with Pulse Frequency
Megacolon
Do Not Combine
Gastrointestinal stenosis
Do Not Combine
Ileus
Do Not Combine
Hydrophthalmos
Do Not Combine
There are 20 known major drug interactions with Akineton.
Common Akineton Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Major
The risk or severity of adverse effects can be increased when Biperiden is combined with Aclidinium.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Biperiden.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Biperiden.
Cimetropium
Major
The risk or severity of adverse effects can be increased when Biperiden is combined with Cimetropium.
Clomipramine
Major
The metabolism of Clomipramine can be decreased when combined with Biperiden.
Akineton Toxicity & Overdose RiskThe lowest dose of Fentanyl to be toxic to rats is 760 mg/kg. Overdoses may cause dilated and sluggish pupils, flushed skin, decreased secretions in the mouth and nose, foul breath, a fever, rapid heartbeat, arrhythmias, decreased bowel sounds, difficulty passing urine, delirium, confusion, agitation, hyperactivity, poor coordination, memory loss, paranoia, aggression, and seizures.
image of a doctor in a lab doing drug, clinical research

Akineton Novel Uses: Which Conditions Have a Clinical Trial Featuring Akineton?

45 active clinical trials are currently investigating the potential of Akineton to provide relief from Parkinson's Disease, Extrapyramidal Disorders and Organophosphorus Compounds.
Condition
Clinical Trials
Trial Phases
Organophosphorus Compounds
0 Actively Recruiting
Extrapyramidal Disorders
0 Actively Recruiting
Poisoning caused by Nicotine
0 Actively Recruiting
Basal Ganglia Diseases
0 Actively Recruiting
Parkinson's Disease
39 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1

Akineton Reviews: What are patients saying about Akineton?

4Patient Review
12/3/2014
Akineton for Extrapyramidal Reaction
I'm back on flupentaxil because I need it for the side effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about akineton

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Akineton?

"The following are symptoms of dry mouth/nose/throat: blurred vision, drowsiness, euphoria or disorientation, urinary retention, dizziness when standing up, constipation, nausea."

Answered by AI

What is Akineton tablets used for?

"Akineton is a prescription medication used to treat symptoms like stiffness, tremors, spasms, and poor muscle control in Parkinson's disease. It can be used alone or with other medications, and belongs to a class of drugs called anticholinerigic drugs."

Answered by AI

What is biperiden used for?

"Biperiden is a medication used to treat Parkinson's disease, either alone or in conjunction with other medications. It works by improving muscle control and reducing stiffness, allowing for more normal movements."

Answered by AI

Is biperiden addictive?

"After the patient stopped taking the drug that was causing their symptoms, their symptoms improved. However, when they started taking the drug again, they experienced similar effects, leading us to believe that they may be addicted to the drug."

Answered by AI

Clinical Trials for Akineton

Have you considered Akineton clinical trials? We made a collection of clinical trials featuring Akineton, we think they might fit your search criteria.Go to Trials
Image of University of Kentucky in Lexington, United States.

Peripheral Nerve Tissue Implantation for Parkinson's Disease

45 - 75
All Sexes
Lexington, KY
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery.
Phase 1
Recruiting
University of KentuckyCraig G van Horne, MD, PhD
Image of Austin Clinic PPD in Austin, United States.

LY3962681 for Parkinson's Disease

30 - 80
All Sexes
Austin, TX
The purpose of this study is to evaluate the safety, tolerability, and PK/PD of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study will be comprised of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Doses (MAD) study. During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid (aCSF), no active drug) given into the spinal fluid. During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered into the spinal fluid. * The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 days, 12 to 24 weeks apart. * The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks post Dose 2.
Phase 1
Recruiting
Austin Clinic PPDTravis LewisPrevail Therapeutics
Image of Edward Hines Jr. VA Hospital, Hines, IL in Hines, United States.

Non-Invasive Vagal Nerve Stimulation for Parkinson's Disease

50 - 88
All Sexes
Hines, IL
More than 110,000 US Veterans living with Parkinson's disease (PD) currently receive PD-related care and services from the VA. Fall prevention is a priority for Veterans living PD. Gait disturbances are a major cause for functional dependence and the largest risk factor for falls, institutionalization, and death in PD. This SPiRE addresses the need to advance nonpharmacological rehabilitative health care of Veterans and maximizing functional outcomes by developing a non-invasive, neuromodulatory transcutaneous cervical Vagal Nerve Stimulation as an at-home intervention to improve gait and balance. This pilot clinical trial will assist with future efforts and priorities of the VA to prolong independent living and quality of life by minimizing gait and balance dysfunction experienced by Veterans living with PD.
Waitlist Available
Has No Placebo
Edward Hines Jr. VA Hospital, Hines, ILSandra L. Kletzel, PhD BA
Have you considered Akineton clinical trials? We made a collection of clinical trials featuring Akineton, we think they might fit your search criteria.Go to Trials
Image of San Francisco VA Medical Center, San Francisco, CA in San Francisco, United States.

Ketamine for Depression in Parkinson's Disease

40 - 80
All Sexes
San Francisco, CA
Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments for depression in PD. Ketamine, which has rapid and potent antidepressant effects, is a potential option but has not been tested in Veterans with PD. Studies in rodents show that ketamine may not only improve depression in PD, it may target two of the underlying drivers of the disease: (1) reduced neuroplasticity, or the brain's ability to adapt and remodel itself; and (2) elevated inflammation. The investigators are conducting a randomized, placebo-controlled study to examine if a dose of intravenous (IV) ketamine improves depression in Veterans with PD. The investigators will also examine ketamine's effects on neuroplasticity and inflammation, which will help us understand how ketamine works in PD and if it can be a useful treatment for Veterans with the disease. This study will lay groundwork for a larger clinical trial across multiple VA sites.
Phase 2
Recruiting
San Francisco VA Medical Center, San Francisco, CAEllen R Bradley, MD
Image of Hunter Holmes McGuire VA Medical Center, Richmond, VA in Richmond, United States.

Exoskeleton for Parkinson's Disease

18 - 90
All Sexes
Richmond, VA
Physical therapy approaches for balance and walking deficits in Parkinson's disease (PD) have limited effectiveness, with mostly short-lasting benefits. An exoskeleton is a device that straps to the legs and provides a passive force to assist people to better ambulate. The goal of this study is to establish the feasibility and safety of a lightweight exoskeleton on mobility and fall reduction in people with PD. As most PD patients eventually require assistive mobility devices, the exoskeleton represents a new option for increased, mobility, quality of life, and independence. Qualified subjects will come to the clinic twice weekly for eight weeks (16 total visits) and wear the exoskeleton device while walking under the supervision of a trained kinesiotherapist. Study staff will also interview participants and assess their PD symptoms, quality of life, and overall mobility. This study hopes to establish exoskeletons as modern, standard of care devices, which allow people with PD to maintain more independent and productive lives.
Recruiting
Has No Placebo
Hunter Holmes McGuire VA Medical Center, Richmond, VA (+1 Sites)Jessica B Lehosit
Image of Stanford Neuroscience Health Center in Stanford, United States.

STN+NBM DBS for Mild Cognitive Impairment in Parkinson's Disease

21 - 80
All Sexes
Stanford, CA
The goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM) to treat cognitive and cognitive-motor symptoms in individuals with Parkinson's disease. The main question it aims to answer is: Is a combined deep brain stimulation approach targeting the STN and NBM with four DBS leads safe and tolerable for cognitive and cognitive-motor symptoms in individuals with Parkinson's disease with Mild Cognitive Impairment. Ten participants are anticipated to be enrolled. Participants will undergo a modification of the traditional STN DBS approach for motor symptoms of PD. In addition to the two leads placed within the STN, two additional leads will be placed with the NBM for treatment of cognitive and cognitive-motor symptoms. Novel stimulation patterns will be used within the NBM to target cognitive and cognitive-motor symptoms using an investigational software. Participants will be followed over two years while receiving this therapy with assessments at baseline and every six months. Assessments will include a combination of neuropsychological evaluations, cognitive assessments, motor tasks (including gait/walking), and questionnaires to evaluate the treatment. Two different surgical trajectories will be used, with half the cohort randomized to each group. This will allow comparison of the impact of surgical trajectory on the intervention.
Recruiting
Has No Placebo
Stanford Neuroscience Health CenterHelen M Bronte-Stewart, MD MSE
Have you considered Akineton clinical trials? We made a collection of clinical trials featuring Akineton, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security